The DOI matches its Crossref record.
6-Mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease
Abstract
BACKGROUND: As treatment of steroid-dependent patients with inflammatory bowel disease (IBD) is controversial, we analysed the efficacy and tolerance of 6-mercaptopurine (6-MP) and methotrexate (MTX) added to prednisone in increasing and maintaining the disease remission rate. METHODS: Seventy-two steroid-dependent IBD patients, 34 with ulcerative colitis (UC) and 38 with Crohn's disease (CD), receiving treatment with prednisone were randomly assigned in a 2:2:1 ratio to additionally receive, orally, over a period of 30 weeks 1.5 mg/kg/day of 6-MP (group A) or 15 mg/week of MTX (group B), or 3 g/day of 5-aminosalicylic acid (5-ASA) (group C). All patients who achieved remission were included in a maintaining remission study for 76 weeks. Remission was defined after stopping prednisone as a CD activity index of <150 and normal serum orosomucoid concentration for CD patients and a Mayo Clinic score <7 for UC patients. RESULTS: With regard to achieved remission, a significantly higher (P< 0.05) rate existed for UC patients in group A (78.6%) than in group C (25%), with no statistical differences in group B (58.3%) versus C. For CD patients, the rates were significantly higher (P< 0.001 and 0.01, respectively) in groups A (93.7%) and B (80%) versus C (14%). With regard to maintaining remission, UC patients in group A (63.6%) presented significantly higher rates (P < 0.0015 and P < 0.001, respectively) versus 14.3% in group B and none in group C. For CD patients, statistical differences (P < 0.001) existed when comparing rates in groups A (53.3%) and B (66.6%) versus none in group C. Noticeable side effects appeared in 13.3% of patients from group A and 11.5% from group B. CONCLUSIONS: These results suggest that 6-MP or MTX added to prednisone could be effective in steroid sparing, as well as in achieving and maintaining remission in steroid-dependent IBD patients. MTX was less effective in maintaining remission in UC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Dignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M., D'Haens, G., D'Hoore, A., Mantzaris, G., Novacek, G., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.002 · Cited by 1,548
ECCO guidelines on therapeutics in Crohn's disease: medical treatment
Torres, J., Bonovas, S., Doherty, G., Kucharzik, T., Gisbert, J. P., Raine, T., Adamina, M., Armuzzi, A., Bachmann, O., Bager, P., et al. (2020) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz180 · Cited by 1,374
Harbord, M., Eliakim, R., Bettenworth, D., Karmiris, K., Katsanos, K., Kopylov, U., Kucharzik, T., Molnár, T., Raine, T., Sebastian, S., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx009 · Cited by 1,180
ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment
Adamina, M., Bonovas, S., Raine, T., Spinelli, A., Warusavitarne, J., Armuzzi, A., Bachmann, O., Bager, P., Biancone, L., Bokemeyer, B., et al. (2020) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz187 · Cited by 1,106
AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis
Feuerstein, J. D., Isaacs, K. L., Schneider, Y., Siddique, S. M., Falck-Ytter, Y., Singh, S., Chachu, K., Day, L., Lebwohl, B., Muniraj, T., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.006 · Cited by 713
Metadata
- Authors
- Maté-Jiménez, J., Hermida, C., Cantero-Perona, J., & Moreno-Otero, R.
- Venue
- European Journal of Gastroenterology & Hepatology
- Published
- 2000-11
- Volume
- 12
- Issue
- 11
- Pages
- 1227-1233
- ISSN
- 0954-691X (ISSN-L)
- OpenAlex
- W2009285886
- Cited by
- 227
- References
- 0
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 6-Mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. https://app.cochat.ai/papers/10.1097/00042737-200012110-00010
- The paper
- Maté-Jiménez, J., Hermida, C., Cantero-Perona, J., & Moreno-Otero, R. (2000). 6-Mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. European Journal of Gastroenterology & Hepatology. https://doi.org/10.1097/00042737-200012110-00010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.